Astellas Receives FDA Approval for a New Product

Friday, August 9, 2013

The U.S. Food and Drug Administration (FDA) recently approved the New Drug Application (NDA) for ASTAGRAF XL™ (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. The full press release can be read here.